01 8Nexavar
02 1NexavarTM
Main Therapeutic Indication : Oncology
Currency : USD
2020 Revenue in Millions : 773
2019 Revenue in Millions : 854
Growth (%) : -9
Main Therapeutic Indication : Oncology
Currency : USD
2021 Revenue in Millions : 479
2020 Revenue in Millions : 773
Growth (%) : -32
Main Therapeutic Indication : Oncology
Currency : USD
2022 Revenue in Millions : 280
2021 Revenue in Millions : 479
Growth (%) : -41
Main Therapeutic Indication : Oncology
Currency : USD
2015 Revenue in Millions : 850
2014 Revenue in Millions : 981
Growth (%) : 15%
Main Therapeutic Indication : Oncology
Currency : USD
2014 Revenue in Millions : 0.30%
2013 Revenue in Millions :
Growth (%) :
Main Therapeutic Indication : Oncology
Currency : USD
2017 Revenue in Millions : 1,034
2016 Revenue in Millions : 1,079
Growth (%) : -4
Main Therapeutic Indication : Oncology
Currency : USD
2016 Revenue in Millions : 922
2015 Revenue in Millions : 946
Growth (%) : -2
Main Therapeutic Indication : Oncology
Currency : USD
2018 Revenue in Millions : 805
2017 Revenue in Millions : 942
Growth (%) : -15%
Main Therapeutic Indication : Oncology
Currency : USD
2019 Revenue in Millions : 770
2018 Revenue in Millions : 776
Growth (%) : -1
LOOKING FOR A SUPPLIER?